Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

Ars Pharmaceuticals, Inc. ( (SPRY)) has released its Q3 earnings. Here is a breakdown of the information Ars Pharmaceuticals, Inc. presented to its investors. ARS Pharmaceuticals, Inc., a ...

Commercial launch of neffy®(epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by ...

Despite a net loss, ARS Pharmaceuticals Inc (SPRY) is optimistic about NEPHI's market potential and strategic global expansion.

Cantor Fitzgerald has recently initiated ARS Pharmaceuticals Inc (SPRY) stock to Overweight rating, as announced on August 20, 2024, according to Finviz. Earlier, on August 13, 2024, Raymond James had ...

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago. These ...

On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. (NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy adrenaline ...

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...

ALK, a global specialty pharmaceutical company focused on allergy and allergic asthma, announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (ARS ...

On Monday, ARS Pharmaceuticals Inc (SPRY) stock saw a modest uptick, ending the day at $14.99 which represents a slight increase of $0.22 or 1.49% from the prior close of $14.77. The stock opened at ...

ARS Pharmaceuticals has a fifty-two week low of $3.38 and a fifty-two week high of $17.08. ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last posted its earnings results on Tuesday, August ...

Short interest in ARS Pharmaceuticals Inc (NASDAQ:SPRY) increased during the last reporting period, rising from 11.10M to 11.92M. This put 23.16% of the company's publicly available shares short.